IP Library › Granted Patent US 11,154,524
Granted Patent B2
US 11,154,524 · App. 16/836,893 · Granted Oct 26, 2021

Therapeutic compositions of decanoic acid and arginine

Inventors: Thomas F. Rau (Heidelberg Heights, AU); Geoffrey W. Rogers (Fitzroy, AU)
Assignee: Wintermute Biomedical, Inc.
A61K31/201A01N33/12A01N37/06A01N37/44A61K31/14A61K31/198A61K31/20A61K47/55A61P31/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,154,524
App. No.
16/836,893
Granted
Oct 26, 2021
Kind
B2
Abstract

Compositions including a complex of fatty acids (e.g., including one or more C4 to C40 fatty acids, such as a C4 to C20 fatty acid) and one or more amino acids (and particularly one or more amino acids having electrically charged basic side chains, e.g., Arginine, Lysine, etc.) for use as an anti-pathogenic composition. In particular, described herein are compositions of decanoic acid:Arginine in which the decanoic acid and Arginine for a complex having a lamellar supramolecular structure.

Claims (22)

1. A composition comprising, as a therapeutic complex, a mixture of decanoic acid: Arginine forming a complex of decanoic acid and Arginine having a molar ratio of between 1:0.6 to 1:1.6.

2. The composition of claim 1 , wherein the mixture of decanoic acid:Arginine comprises a mixture of decanoic acid:L-Arginine.

3. The composition of claim 1 , wherein the composition comprises at least 0.001% w/w of the complex of decanoic acid:Arginine.

4. The composition of claim 1 , wherein the molar ratio of decanoic acid:Arginine is between 1:0.6 to 1:1.2.

5. The composition of claim 1 , wherein the molar ratio of decanoic acid:Arginine is in an approximately 1:1 molar ratio.

6. The composition of claim 1 , wherein the composition is substantially free of cetyl alcohol and Rhein.

7. The composition of claim 1 , wherein the composition is an aqueous composition.

8. The composition of claim 1 , further comprising an excipient, diluent, carrier or fragrance.

9. The composition of claim 8 , wherein said excipient, diluent, carrier or fragrance is suitable for topical application or for use on surfaces.

10. The composition of claim 1 , wherein the composition is configured as a liquid, emulsion, solution, ointment or cream in a form suitable for topical administration to a human or for use on surfaces.

11. The composition of claim 1 , wherein the composition is configured for one or more of: oral, parenteral, intraperitoneal, transmucosal, transdermal, rectal, inhalable, and topical administration.

12. The composition of claim 1 , wherein the composition is configured for administration as a hand sanitizer, surface sanitizer or disinfectant.

13. The composition of claim 1 , further comprising benzalkonium chloride.

14. A composition comprising an aqueous solution of a complex of decanoic acid:L-Arginine as a therapeutic complex and having a molar ratio of decanoic acid:L-Arginine of between 1:0.6 to 1:1.6 at a total concentration of at least about 0.001% w/w, wherein the composition is substantially free of cetyl alcohol.

15. The composition of claim 14 , wherein the molar ratio of decanoic acid:L-Arginine is between 1:0.6 to 1:1.2.

16. The composition of claim 14 , wherein the molar ratio of decanoic acid:L-Arginine is in an approximately 1:1 molar ratio.

17. The composition of claim 14 , further comprising an excipient, diluent, carrier or fragrance.

18. The composition of claim 17 , wherein said excipient, diluent, carrier or fragrance is suitable for topical application or for use on surfaces.

19. The composition of claim 14 , wherein the composition is configured as a liquid, emulsion, solution, ointment or cream in a form suitable for topical administration to a human or for use on surfaces.

20. The composition of claim 14 , wherein the composition is configured for one or more of: oral, parenteral, intraperitoneal, transmucosal, transdermal, rectal, inhalable, and topical administration.

21. The composition of claim 14 , further comprising benzalkonium chloride.

22. The composition of claim 14 , wherein the composition is configured for administration as a hand sanitizer, surface sanitizer or disinfectant.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 9, 2020
From: RAU, THOMAS F.; ROGERS, GEOFFREY W.
To: WINTERMUTE BIOMEDICAL, INC.
Reel/Frame 052886/0844 →
Continuity (5)
Continuation In Part PCTUS2019054044 · Oct 1, 2019
Provisional Application 62739844 · Oct 1, 2018
Provisional Application 62845858 · May 9, 2019
Provisional Application 62845859 · May 9, 2019
Related Publication 20200282067A1 · Sep 10, 2020
Cited By (2)
US 12,186,293 US 12,383,524